Clinical Trial Update: Gecacitinib in the Treatment of Steroid-Refractory/Dependent Chronic Graf Versus Host Disease (cGVHD). [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating gecacitinib for steroid-refractory or dependent chronic graft-versus-host disease (cGVHD) in HSCT patients; currently not ye…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Gecacitinib (Gecacitinib)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: cGVHD, HSCT | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING